http://purl.uniprot.org/citations/15193259 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
http://purl.uniprot.org/citations/15193259 | http://www.w3.org/2000/01/rdf-schema#comment | "R-etodolac, a nonsteroidal anti-inflammatory drug, inhibits the progression of CWRSA6 androgen-independent and LuCaP-35 androgen-dependent prostate cancer xenograft growth through downregulation of cyclin D1 expression via the PPARgamma pathway. PPARgamma protein degradation, observed post-R-etodolac treatment, resulted from phospho-MAP kinase (p44/42) induction by R-etodolac negatively regulating PPARgamma function. Negative regulation of PPARgamma was overcome by a combination regimen of R-etodolac with the HER-kinase axis inhibitor, rhuMab 2C4, which demonstrated an additive antitumor effect. We further show that the inhibition of HER-kinase activity by rhuMab 2C4 is sufficient to inhibit PPARgamma protein degradation. This study introduces a novel concept of an in vivo crosstalk between the HER-kinase axis and PPARgamma pathways, ultimately leading to negative regulation of PPARgamma activity and tumor growth inhibition."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.ccr.2004.05.014"xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Huang G."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Jain A."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Lu D."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Carson D.A."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Holden S."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Corr M."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Leoni L.M."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Agus D.B."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Fox W."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/author | "Hedvat M."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/date | "2004"xsd:gYear |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/name | "Cancer Cell"xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/pages | "565-574"xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/title | "Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma."xsd:string |
http://purl.uniprot.org/citations/15193259 | http://purl.uniprot.org/core/volume | "5"xsd:string |
http://purl.uniprot.org/citations/15193259 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/15193259 |
http://purl.uniprot.org/citations/15193259 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/15193259 |
http://purl.uniprot.org/uniprot/#_E9PFV2-mappedCitation-15193259 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15193259 |
http://purl.uniprot.org/uniprot/#_A0A0S2Z4K5-mappedCitation-15193259 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15193259 |
http://purl.uniprot.org/uniprot/#_A0A3P3ZKM0-mappedCitation-15193259 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15193259 |
http://purl.uniprot.org/uniprot/#_A0A494C1F9-mappedCitation-15193259 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15193259 |
http://purl.uniprot.org/uniprot/#_B6ZGS2-mappedCitation-15193259 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15193259 |